Lack of Benefit of Iron Chelation in Early Parkinson’s Disease
The New England Journal of Medicine , Volume 387, pp 2087-2088; https://doi.org/10.1056/nejme2213120
Abstract: There are no treatments that convincingly slow the progression of Parkinson’s disease. One avenue of investigation is based on iron deposition in the brain, which occurs with aging but is also implicated in neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.1 Iron levels are regulated by binding to transferrin and ferritin, and intracellular iron is partitioned in neurons to prevent toxic effects. Ferroptosis refers to iron-dependent toxicity that triggers lipid peroxidation and other oxidative stresses that lead to cell death.2 Furthermore, cellular iron may exacerbate aggregation of α-synuclein, the neuronal protein that forms Lewy body inclusions . . .
Keywords: cell death / iron / Parkinson / toxicity / stresses / protein / treatments / sup / convincingly slow / body inclusions
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "The New England Journal of Medicine" .